Boston Financial Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$5.86M Buy
32,997
+1,389
+4% +$255K 0.18% 93
2024
Q3
$6.24M Buy
31,608
+1,284
+4% +$240K 0.19% 89
2024
Q2
$5.2M Sell
30,324
-537
-2% -$89K 0.17% 99
2024
Q1
$5.62M Sell
30,861
-20
-0.1% -$3.45K 0.18% 96
2023
Q4
$4.79M Buy
30,881
+5,926
+24% +$864K 0.16% 99
2023
Q3
$3.72M Sell
24,955
-257
-1% -$37.7K 0.14% 104
2023
Q2
$3.4M Sell
25,212
-675
-3% -$99K 0.12% 113
2023
Q1
$4.13M Sell
25,887
-3,683
-12% -$563K 0.16% 102
2022
Q4
$4.78M Buy
29,570
+244
+0.8% +$37.4K 0.19% 92
2022
Q3
$3.94M Buy
29,326
+1,653
+6% +$237K 0.17% 91
2022
Q2
$4.24M Buy
27,673
+892
+3% +$136K 0.18% 87
2022
Q1
$4.34M Buy
26,781
+372
+1% +$54K 0.16% 90
2021
Q4
$3.58M Buy
26,409
+922
+4% +$109K 0.13% 89
2021
Q3
$2.75M Buy
25,487
+566
+2% +$64.7K 0.11% 92
2021
Q2
$2.81M Sell
24,921
-2,025
-8% -$228K 0.11% 91
2021
Q1
$2.92M Sell
26,946
-3,552
-12% -$380K 0.13% 85
2020
Q4
$3.27M Sell
30,498
-5,146
-14% -$495K 0.15% 82
2020
Q3
$3.12M Sell
35,644
-1,287
-3% -$121K 0.15% 83
2020
Q2
$3.63M Sell
36,931
-253
-0.7% -$22.3K 0.2% 80
2020
Q1
$2.83M Sell
37,184
-6,365
-15% -$542K 0.18% 83
2019
Q4
$3.86M Sell
43,549
-3,756
-8% -$312K 0.21% 90
2019
Q3
$3.58M Sell
47,305
-4,204
-8% -$288K 0.2% 94
2019
Q2
$3.75M Sell
51,509
-7,554
-13% -$594K 0.22% 93
2019
Q1
$4.76M Sell
59,063
-4,304
-7% -$352K 0.29% 89
2018
Q4
$5.84M Sell
63,367
-7,185
-10% -$632K 0.4% 77
2018
Q3
$6.67M Buy
70,552
+4,345
+7% +$412K 0.39% 84
2018
Q2
$6.13M Sell
66,207
-29,666
-31% -$2.9M 0.41% 81
2018
Q1
$9.07M Sell
95,873
-8,005
-8% -$879K 0.62% 59
2017
Q4
$10M Sell
103,878
-2,309
-2% -$218K 0.67% 57
2017
Q3
$9.44M Sell
106,187
-15,302
-13% -$1.16M 0.67% 56
2017
Q2
$8.81M Sell
121,489
-4,381
-3% -$295K 0.63% 59
2017
Q1
$8.2M Sell
125,870
-3,270
-3% -$206K 0.61% 61
2016
Q4
$8.09M Sell
129,140
-8,001
-6% -$488K 0.64% 55
2016
Q3
$8.65M Sell
137,141
-14,643
-10% -$948K 0.71% 44
2016
Q2
$9.4M Sell
151,784
-37,167
-20% -$2.26M 0.77% 35
2016
Q1
$10.8M Sell
188,951
-38,721
-17% -$2.16M 1.62% 12
2015
Q4
$13.5M Sell
227,672
-17,342
-7% -$999K 1.93% 5
2015
Q3
$13.3M Sell
245,014
-3,436
-1% -$224K 1.89% 6
2015
Q2
$16.7M Sell
248,450
-11,843
-5% -$773K 2.15% 4
2015
Q1
$15.2M Buy
260,293
+8,956
+4% +$541K 1.91% 5
2014
Q4
$16.4M Sell
251,337
-18,061
-7% -$1.14M 2.07% 4
2014
Q3
$15.6M Sell
269,398
-4,570
-2% -$254K 2.04% 4
2014
Q2
$15.5M Sell
273,968
-39,540
-13% -$2.07M 2.04% 4
2014
Q1
$16.1M Sell
313,508
-3,990
-1% -$202K 2.16% 4
2013
Q4
$16.8M Buy
317,498
+9,105
+3% +$447K 2.3% 3
2013
Q3
$13.8M Sell
308,393
-7,764
-2% -$344K 2.07% 6
2013
Q2
$13.1M Buy
+316,157
New +$13.8M 2.02% 6

Other funds holding ABBV

Boston Financial Management's ABBV Position: Q4 2024 in Review

Boston Financial Management increased its AbbVie (ABBV) stake by 4.4% in Q4 2024, buying an estimated $255K and bringing the position to 32,997 shares worth $5.86M. The position accounts for 0.18% of the portfolio, ranked #93.

Boston Financial Management first reported a position in ABBV in Q2 2013 and has held it in 47 quarters since. The position peaked at $16.8M in Q4 2013. 3,745 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Boston Financial Management held 32,997 shares of AbbVie worth $5.86M as of Q4 2024.
  • Boston Financial Management bought 1,389 AbbVie shares in Q4 2024, an estimated $255K.
  • AbbVie made up 0.18% of Boston Financial Management's portfolio in Q4 2024, its #93 holding.
  • Boston Financial Management first reported a position in AbbVie in Q2 2013 and has held it in 47 quarters since.
  • Boston Financial Management's AbbVie position peaked at $16.8M in Q4 2013.
  • 3,745 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Boston Financial Management's 13F filing for Q4 2024, filed 3 Feb 2025.